Research in Motion (RIMM) estimates cut at JP Morgan through 2014, JP Morgan said. Weaker outlook for Blackberry 7 sales.
Sarepta (SRPT) estimates, target boosted at JMP. Shares of SRPT now seen reaching $50, according to JMP Securities. Estimates also upped, given the clinical efficacy of its muscular dystrophy drug. Outperform rating.
>To submit a news tip, email: email@example.com.
Twitter and become a fan on Facebook.